Literature DB >> 27660144

Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Dustin W Wooten1,2, Nicolas J Guehl1,2, Eline E Verwer1,2, Timothy M Shoup1,2, Daniel L Yokell1,2, Nevena Zubcevik3, Neil Vasdev1,2, Ross D Zafonte3,4, Keith A Johnson2, Georges El Fakhri1,2, Marc D Normandin5,2.   

Abstract

18F-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI). The current study characterizes 18F-T807 pharmacokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input functions.
Methods: Nine subjects (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of 18F-T807 with arterial blood sampling. Total volume of distribution (VT) was estimated using compartmental modeling (1- and 2-tissue configurations) and graphical analysis techniques (Logan and multilinear analysis 1 [MA1] regression methods). Reference region-based methods of quantification were explored including Logan distribution volume ratio (DVR) and static SUV ratio (SUVR) using the cerebellum as a reference tissue.
Results: The percentage of unmetabolized 18F-T807 in plasma followed a single exponential with a half-life of 17.0 ± 4.2 min. Metabolite-corrected plasma radioactivity concentration fit a biexponential (half-lives, 18.1 ± 5.8 and 2.4 ± 0.5 min). 18F-T807 in gray matter peaked quickly (SUV > 2 at ∼5 min). Compartmental modeling resulted in good fits, and the 2-tissue model with estimated blood volume correction (2Tv) performed best, particularly in regions with elevated binding. VT was greater in mild cognitive impairment subjects than controls in the occipital, parietal, and temporal cortices as well as the posterior cingulate gyrus, precuneus, and mesial temporal cortex. High focal uptake was found in the posterior corpus callosum of a TBI subject. Plots from Logan and MA1 graphical methods became linear by 30 min, yielding regional estimates of VT in excellent agreement with compartmental analysis and providing high-quality parametric maps when applied in voxelwise fashion. Reference region-based approaches including Logan DVR (t* = 55 min) and SUVR (80- to 100-min interval) were highly correlated with DVR estimated using 2Tv (R2 = 0.97, P < 0.0001).
Conclusion: 18F-T807 showed rapid clearance from plasma and properties suitable for tau quantification with PET. Furthermore, simplified approaches using DVR (t* = 55 min) and static SUVR (80-100 min) with cerebellar reference tissue were found to correlate highly with compartmental modeling outcomes.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-T807; PET; kinetic modeling; pharmacokinetics; tau

Mesh:

Substances:

Year:  2016        PMID: 27660144      PMCID: PMC5334185          DOI: 10.2967/jnumed.115.170910

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  32 in total

1.  Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease.

Authors:  E D Agdeppa; V Kepe; J Liu; S Flores-Torres; N Satyamurthy; A Petric; G M Cole; G W Small; S C Huang; J R Barrio
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

2.  MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence--initial experience in the brain.

Authors:  M Brant-Zawadzki; G D Gillan; W R Nitz
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

Review 3.  Revisiting an old issue: the discrepancy between tissue ratio-derived binding parameters and kinetic modeling-derived parameters after a bolus of the serotonin transporter radioligand 123I-ADAM.

Authors:  Mark Slifstein
Journal:  J Nucl Med       Date:  2008-02       Impact factor: 10.057

4.  A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807.

Authors:  Timothy M Shoup; Daniel L Yokell; Peter A Rice; Raul N Jackson; Eli Livni; Keith A Johnson; Thomas J Brady; Neil Vasdev
Journal:  J Labelled Comp Radiopharm       Date:  2013-07-24       Impact factor: 1.921

5.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.

Authors:  Sergey Shcherbinin; Adam J Schwarz; Abhinay Joshi; Michael Navitsky; Matthew Flitter; William R Shankle; Michael D Devous; Mark A Mintun
Journal:  J Nucl Med       Date:  2016-05-05       Impact factor: 10.057

6.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

7.  The spectrum of disease in chronic traumatic encephalopathy.

Authors:  Ann C McKee; Robert A Stern; Christopher J Nowinski; Thor D Stein; Victor E Alvarez; Daniel H Daneshvar; Hyo-Soon Lee; Sydney M Wojtowicz; Garth Hall; Christine M Baugh; David O Riley; Caroline A Kubilus; Kerry A Cormier; Matthew A Jacobs; Brett R Martin; Carmela R Abraham; Tsuneya Ikezu; Robert Ross Reichard; Benjamin L Wolozin; Andrew E Budson; Lee E Goldstein; Neil W Kowall; Robert C Cantu
Journal:  Brain       Date:  2012-12-02       Impact factor: 13.501

8.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease.

Authors:  Ryuichi Harada; Nobuyuki Okamura; Shozo Furumoto; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Tetsuro Tago; Kotaro Hiraoka; Shoichi Watanuki; Miho Shidahara; Masayasu Miyake; Yoichi Ishikawa; Rin Matsuda; Akie Inami; Takeo Yoshikawa; Yoshihito Funaki; Ren Iwata; Manabu Tashiro; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

9.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

Review 10.  FSL.

Authors:  Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

View more
  35 in total

1.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

2.  Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Authors:  Kerstin Heurling; Ruben Smith; Olof T Strandberg; Martin Schain; Tomas Ohlsson; Oskar Hansson; Michael Schöll
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-03       Impact factor: 6.200

3.  Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study.

Authors:  Hanna Cho; Jae Yong Choi; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Clifford R Jack; Chul Hyoung Lyoo
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

4.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

5.  PET imaging of tau protein targets: a methodology perspective.

Authors:  Cristina Lois; Ivan Gonzalez; Keith A Johnson; Julie C Price
Journal:  Brain Imaging Behav       Date:  2019-04       Impact factor: 3.978

6.  Subthreshold Amyloid Predicts Tau Deposition in Aging.

Authors:  Stephanie L Leal; Samuel N Lockhart; Anne Maass; Rachel K Bell; William J Jagust
Journal:  J Neurosci       Date:  2018-04-23       Impact factor: 6.167

7.  Impairment of cerebrovascular reactivity in response to hypercapnic challenge in a mouse model of repetitive mild traumatic brain injury.

Authors:  Cillian E Lynch; Maxwell Eisenbaum; Moustafa Algamal; Matilde Balbi; Scott Ferguson; Benoit Mouzon; Nicole Saltiel; Joseph Ojo; Ramon Diaz-Arrastia; Mike Mullan; Fiona Crawford; Corbin Bachmeier
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-13       Impact factor: 6.200

8.  In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls.

Authors:  Tobey J Betthauser; Karly A Cody; Matthew D Zammit; Dhanabalan Murali; Alexander K Converse; Todd E Barnhart; Charles K Stone; Howard A Rowley; Sterling C Johnson; Bradley T Christian
Journal:  J Nucl Med       Date:  2018-05-18       Impact factor: 10.057

9.  Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.

Authors:  Anne Maass; Samuel N Lockhart; Theresa M Harrison; Rachel K Bell; Taylor Mellinger; Kaitlin Swinnerton; Suzanne L Baker; Gil D Rabinovici; William J Jagust
Journal:  J Neurosci       Date:  2017-11-30       Impact factor: 6.167

10.  Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease.

Authors:  Michael Honer; Luca Gobbi; Henner Knust; Hiroto Kuwabara; Dieter Muri; Matthias Koerner; Heather Valentine; Robert F Dannals; Dean F Wong; Edilio Borroni
Journal:  J Nucl Med       Date:  2017-09-28       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.